Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Bone Marrow Transplant ; 32(3): 293-8, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12858201

ABSTRACT

The impact of peripheral blood stem cell transplantation (PBSCT) on survival relative to bone marrow transplantation (BMT) remains poorly defined. Several randomized controlled trials (RCTs) comparing HLA-matched related PBSC- and BMT for patients with hematologic malignancies have been published, yielding differing results. We conducted a meta-analysis of published RCTs to more precisely estimate the effect of PBSCT on survival. Seven trials that assessed survival were identified and included in our analysis. Using a fixed effects model, and combining the results of all seven trials, the summary odds ratio for mortality after PBSCT was 0.81 (95% CI, 0.62-1.05) when compared to BMT. Subgroup analysis revealed no association between the median PBSCT 34+ cell dose and relative risk for morality after PBSCT. However, there was an association between the proportion of patients enrolled with advanced-stage disease and the summary odds ratio for mortality. The pooled estimate was 0.64 for studies where patients with intermediate/advanced disease comprised at least 25% of enrollment, and was 1.07 for the studies enrolling a smaller proportion. This finding substantiates results from previously published studies that have demonstrated a survival advantage with PBSCT limited to patients with advanced disease.


Subject(s)
Bone Marrow Transplantation/mortality , Hematologic Neoplasms/therapy , Histocompatibility , Peripheral Blood Stem Cell Transplantation/mortality , Adult , Antigens, CD34 , Cell Count , Disease Progression , Female , HLA Antigens , Hematologic Neoplasms/mortality , Humans , Male , Middle Aged , Odds Ratio , Randomized Controlled Trials as Topic/statistics & numerical data , Risk Factors , Survival Analysis , Transplantation, Homologous
2.
Am J Respir Cell Mol Biol ; 24(1): 12-21, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11152645

ABSTRACT

Fibrinogen (FBG), together with its polymerized form fibrin, modulates cellular responses during wound repair and tissue remodeling. Thus, we sought to determine whether A549 lung epithelial type II-like cells would endocytose insoluble, surface-bound FBG as a potential mechanism of alveolar matrix remodeling. Surface-bound FBG was endocytosed into either lysosomes or late endosomes by A549 cells through arg-gly-asp-dependent binding to alphavbeta3 but not alpha5beta1 integrin receptors. Soluble FBG added to confluent monolayers of A549 cells was not endocytosed. Unlike the uptake of the extracellular matrix glycoproteins vitronectin and thrombospondin by other cell types, endocytosis of FBG by A549 cells was neither inhibited by heparin nor dependent on binding to cell-surface heparan sulfate proteoglycans. FBG did not colocalize with endocytosed transferrin, whereas dextran showed partial colocalization with FBG in endocytic vesicles, suggesting nonclathrin-mediated endocytosis. Inhibition of actin filament polymerization blocked endocytosis of both dextran and FBG but not transferrin, providing further support that FBG is endocytosed via a nonclathrin pathway. Disruption of actin polymerization inhibited integrin-mediated cell spreading, which contributed to an overall reduction in FBG clearance that was most likely due to reduced cell migration and associated pericellular proteolysis. Trasylol inhibition of extracellular plasmin activity did not inhibit endocytosis of FBG. The endocytosed FBG was degraded to trichloroacetic acid-soluble fragments that showed an electrophoretic pattern distinctly different from plasmin-degraded FBG. Together, these results suggest that endocytosis of matrix-associated FBG by alveolar epithelial cells may be involved in the processes of alveolar tissue repair and matrix remodeling.


Subject(s)
Endocytosis/physiology , Fibrinogen/metabolism , Pulmonary Alveoli/metabolism , Receptors, Vitronectin/metabolism , Cell Line , Clathrin/metabolism , Endocytosis/drug effects , Epithelial Cells/metabolism , Fibrinolysin/metabolism , Fibrinolysin/pharmacology , Heparin/analogs & derivatives , Heparin/metabolism , Humans , Integrins/metabolism , Lysosomes/metabolism , Oligopeptides/pharmacology , Peptide Hydrolases/metabolism , Peptide Hydrolases/pharmacology , Protein Processing, Post-Translational/drug effects , Proteoglycans/metabolism , Pulmonary Alveoli/cytology , Pulmonary Alveoli/drug effects
3.
Catheter Cardiovasc Interv ; 49(1): 56-60, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10627368

ABSTRACT

We present a case of arterial thrombosis of the upper extremity in a 1-day-old neonate. The initial response to thrombolytic and anticoagulant therapy alone was unsuccessful. Distal flow to the extremity was reestablished by combined percutaneous transluminal angioplasty of the subclavian artery using transumbilical access followed by resumption of the thrombolytic and anticoagulant regimen. Cathet. Cardiovasc. Intervent. 49:56-60, 2000.


Subject(s)
Angioplasty, Balloon , Subclavian Artery , Thrombosis/therapy , Female , Humans , Infant, Newborn , Radiography , Subclavian Artery/diagnostic imaging , Thrombosis/congenital , Thrombosis/diagnostic imaging
4.
Infect Immun ; 66(3): 1070-5, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9488397

ABSTRACT

The vascular endothelial cell (EC) is a primary target of infection with Rickettsia rickettsii, the etiologic agent of Rocky Mountain spotted fever. Changes in gene transcription elicited by intracellular infection, including EC expression of the coagulation pathway initiator known as tissue factor (TF), may contribute to the vascular pathology observed during disease. Nuclear run-on analysis of uninfected and infected, cultured human endothelial cells revealed that the rate of TF mRNA transcription is enhanced more than twofold at 3 h following infection, thus coinciding with increased steady-state levels of TF mRNA. TF mRNA remained relatively unstable during infection, with a half-life of 1.6 h. The eukaryotic protein synthesis inhibitor cycloheximide did not block R. rickettsii-induced increase in TF mRNA levels and actually resulted in its superinduction, thus revealing that de novo synthesis of host cell protein was not prerequisite to this transcriptional response. Involvement of the transcription factor NF-kappaB in R. rickettsii-induced TF expression was demonstrated by using two unrelated inhibitors of NF-kappaB activation. The antioxidant pyrrolidinedithiocarbamate and the proteasome inhibitor N-tosyl-L-phenylalanine chloromethyl ketone blocked expression of TF mRNA and activity during infection. This study demonstrates that R. rickettsii infection results in transcriptional activation of the TF gene and that this response involves activation of the transcription factor NF-kappaB.


Subject(s)
Endothelium, Vascular/metabolism , Gene Expression Regulation , NF-kappa B/physiology , Rocky Mountain Spotted Fever/metabolism , Thromboplastin/biosynthesis , Cells, Cultured , Cycloheximide/pharmacology , Humans , Proline/analogs & derivatives , Proline/pharmacology , RNA, Messenger/analysis , Thiocarbamates/pharmacology , Thromboplastin/genetics , Tosylphenylalanyl Chloromethyl Ketone/pharmacology , Transcription, Genetic
5.
Infect Immun ; 65(7): 2786-91, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9199451

ABSTRACT

Rickettsia rickettsii, the etiologic agent of Rocky Mountain spotted fever, is an obligate intracellular bacterial organism that infects primarily the vascular endothelial cells (EC). A component of the EC response to infection is transcriptional activation, which may contribute to the thrombotic and inflammatory consequences of disease. In this study, we explore R. rickettsii-induced activation of the nuclear factor-kappaB/Rel (NF-kappaB) family of transcription factors involved in early transcriptional responses to injurious stimuli. Two NF-kappaB species were activated by infection and reacted with a double-stranded oligonucleotide probe corresponding to the kappaB binding domain of the murine kappa light-chain gene enhancer. Gel supershift analysis demonstrated the reactivity of these complexes with antibodies against p65 and p50, and the induced species were tentatively identified as p50-p50 homodimers and p50-p65 heterodimers. Semiquantitative reverse transcription-PCR analysis revealed dramatic increases in the steady-state levels of mRNA coding for the inhibitory subunit of NF-kappaB (IkappaB alpha), transcription of which is enhanced by the binding of NF-kappaB within the IkappaB alpha promoter region. NF-kappaB activation was first detected 1.5 h following infection and was biphasic, with an early peak of activation at approximately 3 h, a return to baseline levels at 14 h, and even higher levels of activation at 24 h. It is likely that NF-kappaB activation requires cellular uptake of R. rickettsii, since treatment of EC with cytochalasin B during infection to block entry inhibited activation by only 70% at 3 h. R. rickettsii-induced activation of NF-kappaB may be an important controlling factor in the transcriptional responses of EC to infection with this obligate intracellular organism.


Subject(s)
Endothelium, Vascular/microbiology , NF-kappa B/physiology , Rickettsia rickettsii/physiology , Cells, Cultured , Cytochalasins/pharmacology , Humans , Promoter Regions, Genetic , Transcription, Genetic
6.
Blood ; 77(9): 1876-83, 1991 May 01.
Article in English | MEDLINE | ID: mdl-1708291

ABSTRACT

The c-kit proto-oncogene encodes a 145- to 160-Kd transmembrane tyrosine kinase, which is a member of the platelet-derived growth factor receptor family and is allelic with the murine white spotting locus (W). W mutations affect several aspects of hematopoiesis, most notably erythroid progenitors and mast cells. A monoclonal antibody, YB5.B8, had been raised against the leukemic blasts of a patient with M1-type acute myelocytic leukemia (AML) and it precipitates a 150-Kd cell surface glycoprotein from leukemic cells. The YB5.B8 epitope is expressed on mast cells, on up to 3% of normal mononuclear bone marrow cells, and it identifies a sub-group of AML patients with a poor prognosis. In view of similarities noted between the cell surface antigen identified by YB5.B8 and the c-kit protein product, we performed experiments to determine whether they are identical. c-kit RNA expression in the cell lines HEL (human erythroleukemia) and A172 (glioblastoma) was shown to parallel the expression of the YB5.B8 epitope in these lines as measured by flow cytometry. Immunoprecipitation analysis with anti-kit serum and YB5.B8 antibody indicated that the two antibodies identified proteins of identical size in HEL (155 Kd) and A172 (145 Kd) cells, and sequential immunoprecipitations with the kit and the YB5.B8 antibodies demonstrated that the two antibodies recognize the same molecule. The proteins identified by both the anti-kit and YB5.B8 antibodies displayed in vitro autophosphorylation activity in immune complex kinase assays. In addition, YB5.B8 was able to inhibit the binding of the kit ligand to HEL cells. These studies provide evidence that the YB5.B8 antigen and the c-kit protein product are identical and raise certain hypotheses regarding the role of c-kit in AML.


Subject(s)
Antibodies, Monoclonal , Proto-Oncogene Proteins/analysis , Antibodies, Monoclonal/immunology , Antigens, Neoplasm/analysis , Epitopes/immunology , Flow Cytometry , Gene Expression , Glioma/immunology , Glioma/metabolism , Humans , Immunosorbent Techniques , Leukemia, Erythroblastic, Acute/immunology , Leukemia, Erythroblastic, Acute/metabolism , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/metabolism , Mast Cells/immunology , Proto-Oncogene Mas , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/immunology , Proto-Oncogene Proteins c-kit , RNA/genetics , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...